Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls

Erik Pålsson1 • Carl Sellgren6,7 • Eleonore Rydén2 • Ruth Kizza2 • Aurimantas Pelanis3 • Henrik Zetterberg1,4,5 • Kaj Blennow1,4 • Mikael Landén1,8

Abstract Alterations in monoaminergic signaling are suggested as key aspects of the pathophysiology in bipolar disorder and ADHD, but it is not known if the monoamine metabolic profile differs between these disorders. One method to study monoaminergic systems in humans is to measure monoamine end-point metabolite concentrations in cerebrospinal fluid (CSF). Here, we analyzed CSF monoamine metabolite concentrations in 103 adults with bipolar disorder, 72 adults with ADHD, and 113 controls. Individuals with bipolar disorder had significantly higher homovanillic acid (HVA, 264 ± 112 nmol/L, p < 0.001) and 5-hydroxyindoleacetic acid (5-HIAA, 116 ± 42 nmol/L, p = 0.001) concentration, but lower 3-methoxy-4-hydroxyphenylethanol (MHPG, 38 ± 8 nmol/L, p < 0.001) concentrations than controls (HVA, 206 ± 70 nmol/L; 5-HIAA, 98 ± 31 nmol/L; and MHPG, 42 ± 7 nmol/L). Higher HVA concentrations were associated with a history of psychosis in the bipolar disorder sample. Subjects with ADHD had higher HVA (240 ± 94 nmol/L, p < 0.001) concentrations compared with controls. In addition, SSRI treatment was associated with lower 5-HIAA concentrations in both patient groups. A power analysis indicated that for within-group comparisons, only large effects would be reliably detectable. Thus, there may be moderate-to-small effects caused by medication that were not detected due to the limited size of the sub-groups in these analyses. In conclusion, the present study suggests disorder-specific alterations of CSF monoamine metabolite concentrations in patients with bipolar disorder and ADHD compared with controls; these differences were independent of acute symptoms and medication effects.

Keywords Bipolar disorder • ADHD • Cerebrospinal fluid • Dopamine • Serotonin • Norepinephrine • Monoamines

Introduction

According to the monoamine hypothesis of mood disorders, based on pharmacological studies from the end of the 1950s and onwards (Akiskal and McKinney 1973), alterations in monoaminergic signaling are key aspects of the pathophysiology in several psychiatric disorders. A central tenet is that depression is caused by reduced activity in the monoaminergic signaling systems and that symptoms are alleviated by increasing monoaminergic activity [although subsequent work paints a more complex picture (Owens
Contrariwise, the hypothesis predicts that increased monoaminergic activity is the pathophysiological basis for mania (Tissot 1975). A monoaminergic hypothesis of attention-deficit/hyperactivity disorder (ADHD) was suggested in the early 1970s (Kornetsky 1970) and implicates a dysregulated noradrenergic, dopaminergic, and probably serotonergic, signaling (Biederman and Spencer 1999; Bonvicini et al. 2016). Despite tremendous efforts to probe pathophysiological aberrations in monoamine signaling in patients with mood disorders and ADHD, the nature of such changes remains unclear (Chaudhury et al. 2015). The strongest argument in support of this hypothesis is still that drugs targeting brain monoamine signaling are effective across several psychiatric disorders including schizophrenia, major depressive disorder, bipolar disorder, and ADHD.

One method to study the monoaminergic systems in humans is to measure the end-metabolites of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) in cerebrospinal fluid (CSF). Sampling of CSF provides an indirect measure of brain monoamine concentrations as compared to the study of urine or blood that merely provides information on peripheral concentrations. Indeed, CSF concentrations of the DA metabolite homovanillinic acid (HVA) and the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) correlate highly with the brain tissue concentrations in dogs (Moir et al. 1970). Moreover, experiments in rats have shown that CSF HVA and 5-HIAA concentrations are indicative of brain DA and 5-HT turnover (Nielsen and Moore 1982).

In support of the monoamine theory of mood disorders, low CSF concentrations of HVA and 5-HIAA have been associated with depressive symptoms in patients with mood disorders (Agren 1980; Kasa et al. 1982; Peabody et al. 1987; Asberg et al. 1984). Observations in patients with mania are inconsistent and report increased, decreased, or unchanged HVA and 5-HIAA concentrations (Goodwin and Ghaemi 1998; Shah and Yatham 2000; Gerner et al. 1984; Swann et al. 1983). Furthermore, acute mania or atypical symptoms of depression have been associated with higher concentrations of the NE metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in CSF from patients with a mood disorder (Swann et al. 1994; Redmond et al. 1986). Finally, CSF concentrations of HVA, 5-HIAA, and MHPG have been positively associated with ADHD symptoms (Castellanos et al. 1994).

In summary, findings suggest that CSF monoamine metabolites are state markers of elevated and depressed mood, as well as attention-deficit or hyperactivity symptoms. Much less is known about CSF monoamine metabolite status as a trait marker in clinically recovered patients. Euthymic bipolar patients have a high likelihood of relapse, even though they do not suffer from acute mood symptoms. A single study that included 25 euthymic patients with bipolar disorder and 30 healthy controls found no group differences in CSF monoamine metabolite concentrations (Berrettini et al. 1985). However, in a previous study, we found lower concentrations of HVA and 5-HIAA in bipolar disorder patients with comorbid ADHD as compared to patients with pure bipolar disorder (Ryden et al. 2009).

The aim of this study was to investigate whether CSF monoamine metabolite concentrations differ between: (a) patients with bipolar disorder and healthy controls, (b) patients with ADHD and healthy controls, and (c) patients with bipolar disorder and patients with ADHD. We thus sampled CSF from three groups: mood-stable adults with bipolar disorder, adults with ADHD, and population-based healthy controls.

**Methods**

The present study is part of the St. Göran project, which provides assessment, treatment, and follow-up of patients with bipolar disorder and ADHD within the Northern Stockholm Mental Health Service. The inclusion criteria for individuals with bipolar disorder have previously been outlined in detail (Ekman et al. 2010). The key clinical assessment instrument used was the Affective Disorder Evaluation (ADE), which was developed for the Systematic Treatment Enhancement Program of Bipolar Disorder (STEP-BD) (Sachs et al. 2003). In addition to the ADE, the structured psychiatric interview, Mini International Neuropsychiatry Interview (M.I.N.I.) (Sheehan et al. 1998), was completed at baseline to screen for other psychiatric diagnoses than bipolar disorder. In addition, the Alcohol Use Disorders Identification Test (AUDIT) and Drug Use Disorders Identification Test (DUDIT) were also used to screen for substance abuse disorder. The full diagnostic assessment was based on all available sources of information, including patient interviews, case records, and, if possible, interviews with the next of kin. The diagnoses were established at diagnostic case conferences where all information available at the time of enrollment was presented. A consensus panel of experienced board certified psychiatrists specialized in bipolar disorder made a best-estimate diagnostic decision. To be included, patients were required to be 18 years or older and to meet DSM-IV criteria for bipolar spectrum disorders (i.e., type I, type II, or not otherwise specified). We collected information on age; sex; number of lifetime manic, hypomanic, depressive, and total episodes; duration of illness, defined as years since first hypomanic, or manic episode; age at onset of illness, defined as age at first hypomanic or manic episode; family history of bipolar disorder (first- or second-degree
relatives with bipolar disorder); years of education; primary source of income; body mass index (BMI); and previous psychotic episodes. The severity of bipolar disorder was rated using the Clinical Global Impression (CGI) rating scales and Global Assessment of Functioning (GAF). For ethical reasons, patients continued to take their prescribed medications at the time of CSF and blood sampling.

Subjects with ADHD were enrolled from a tertiary care outpatient unit specialized in assessment and treatment of ADHD and related syndromes. One board certified psychiatrist (E.R.) interviewed all cases according to a structured intake-interview. This protocol builds on the ADE chiatrist (E.R.) interviewed all cases according to a structured interview and assessment with the Structured Clinical Interview and assessment with the Structured Clinical Interview and Assessment for DSM-IV Axis II Personality Disorders). We screened for substance abuse in several ways: during the telephone interview, during the psychiatric in-person interview, using the Alcohol Use Disorders Identification Test (AUDIT) and Drug Use Disorders Identification Test (DUDIT), and by determining serum concentrations of carbohydrate-deficient transferrin (CDT). Overconsumption of alcohol, as revealed by CDT or responses indicating large consumption (>8 standard drinks per time more than twice per week) and/or amnesia and/or loss of control more than once per month, resulted in the exclusion of these individuals from the study. Other exclusion criteria were neurologic conditions other than mild migraines, untreated endocrinological disorders, pregnancy, dementia, recurrent depressive disorder and suspected severe personality disorders (based on a psychiatric interview and assessment with the Structured Clinical Interview for DSM-IV Axis II Personality Disorders), and a family history of schizophrenia or bipolar disorder in the first-degree relatives.

**CSF sampling**

Bipolar disorder patients were not experiencing any acute mood episode at time of blood and CSF sampling. CSF was sampled by means of a lumbar puncture conducted between 9 and 10 am after an overnight fast. We collected a total volume of 12 mL CSF and gently inverted it to avoid gradient effects. CSF samples were divided into aliquots that were stored at −80 °C pending analysis at the Biobank at Karolinska Institutet, Stockholm, Sweden. Cases and controls underwent an identical procedure.

**Analysis of monoamines**

Determination of the monoamine metabolites was performed by means of high-performance liquid chromatography with electrochemical detection, as described by Blennow et al. (1993). Intra- and inter-assay coefficients of variation were below 5% for all three analytes.

**Study population**

Study data were selected from the St. Göran research database, which is an SQL-based database hosted by Gothenburg University. Data were extracted in January 2016 when the database contained information on 337 patients with bipolar disorder, 91 patients with ADHD, and 116 controls recruited in Stockholm. The inclusion criteria for this study were that each individual had to have data on monoamine metabolite concentrations and anamnestic information. For bipolar disorder, all diagnostic sub-groups with a verified bipolar disorder diagnosis were included, whereas individuals with schizoaffective disorder were excluded. In a final step, all patients with bipolar disorder with evidence of ADHD comorbidity were also excluded. Here, ADHD comorbidity was defined as a past or current M.I.N.I diagnosis, a lifetime ADHD diagnosis as defined in our previously published studies (Ryden et al. 2009), or current central stimulant treatment. This left 103 patients with bipolar disorder, 72 patients with ADHD, and 113 controls. Data on CSF monoamine concentrations for a subset of bipolar disorder patients and controls from the Stockholm center have been presented previously (Ryden et al. 2009; Sellgren et al. 2015).

**Statistics**

SPSS v 20.0 was used for all statistical analysis except the power analysis (G*power v 3.1.9.2). Chi-square and ANOVA tests were used for comparisons between the three study groups, followed by Bonferroni post hoc tests. Independent sample t tests were used for bivariate group comparisons of continuous outcome variables. Levene’s test was used to test equality of variance across groups and non-homoscedastic variables were log10-transformed prior to analysis. Corrections for multiple tests were performed using the Bonferroni method. A power analysis indicated...
that the size of the study groups would give a power of 0.95 for detecting medium-sized effects in the between-group comparisons. For within-group comparisons, the power analyses indicated that only large effects would be reliably detectable. In all analyses, a two-sided \( p \) value of less than 0.05 was regarded to be statistically significant.

**Ethics**

The Regional Ethics Committee in Stockholm approved our study (2005/554-31/3), which we conducted in accordance with the latest Helsinki Protocol. All patients and controls consented orally and in writing to participate in the study.

**Results**

**Sample characteristics**

The previous work has shown that age, sex, and body height can influence the concentrations of CSF monoamine metabolites (Blennow et al. 1993). The distributions of age, body height, and sex for the patient and control groups are shown in Table 1. One control subject had an MHPG concentration >3 standard deviations above the group mean and this observation was regarded as an outlier and excluded from all subsequent analysis. Since the three groups did not differ regarding age, sex, and body height, subsequent group comparisons were performed without correction for these covariates.

**Monoamine metabolite concentrations and diagnosis**

Group comparisons of CSF monoamine metabolite concentrations are shown in Fig. 1. The bipolar disorder group had significantly higher HVA (264 ± 112 nmol/L, \( p < 0.001 \), ANOVA with Bonferroni post hoc test) and 5-HIAA (116 ± 42 nmol/L, \( p = 0.001 \), ANOVA with Bonferroni post hoc test) concentrations, than the control group (206 ± 70 and 98 ± 31 nmol/L, respectively). Furthermore, the ADHD group demonstrated significantly higher HVA (240 ± 94 nmol/L, \( p < 0.001 \), ANOVA with Bonferroni post hoc test) but not 5-HIAA (103 ± 32 nmol/L) concentrations as compared to the control group. In addition, patients with bipolar disorder had lower MHPG (38 ± 8 nmol/L, \( p < 0.001 \), ANOVA with Bonferroni post hoc test) concentrations than both healthy controls (42 ± 7 nmol/L) and patients with ADHD (43 ± 9 nmol/L). Finally, we recently found increased CSF concentrations of HVA in 35 euthymic bipolar patients with a history of psychosis, while the 37 bipolar patients without such a history did not differ significantly from controls (Sellgren et al. 2015). This effect was also evident here using an independent sample \( t \) test to compare patients bipolar disorder with and without a history of psychosis (unpaired \( t \) test, \( t = 3.8, p < 0.001 \)). After exclusion of all patients with a history of psychosis, the difference between patients with bipolar disorder and healthy controls was no longer statistically significant (unpaired \( t \) test, \( t = 1.4, p = 0.16 \)). Given that only one patient in the ADHD group had a history of psychotic symptoms, we did not perform the same analysis for that cohort. The clinical characteristics of the two patient groups are shown in Table 2.

**Medication**

To reduce the risk of false positive associations, only associations that have been previously reported were tested. For HVA, these included putative associations with lithium (Fyro et al. 1975), valproate (MacMillan et al. 1987), central stimulant (Castellanos et al. 1996), and antipsychotic (Nikisch et al. 2010; Scheepers et al. 2001) treatment. For 5-HIAA, associations with lithium (Fyro et al. 1975), valproate (MacMillan et al. 1987), and antidepressant (Backman et al. 2000) treatment were explored. Finally, for MHPG, associations with lithium (Swann et al. 1987), central stimulant (Elia et al. 1990), and antidepressant (Backman et al. 2000) treatment were tested. The effect of antidepressant treatment was tested using SSRI:s, SNRI:s, and other antidepressants as individual fixed factors in a general linear model. All other treatment effects were assessed using bivariate group comparisons using independent \( t \) tests. The only statistically significant associations demonstrated in the bipolar disorder group were lower 5-HIAA (general linear model, \( F = 7.3, p = 0.008 \)) and MHPG (general linear model, \( F = 4.8, p = 0.013 \)) concentrations in individuals treated with SSRIs. In the ADHD group, 5-HIAA concentrations were lower in persons treated with SSRI:s (general linear model, \( F = 7.1, p = 0.01 \)) or SNRI:s (general linear model, \( F = 4.4, p = 0.04 \). Finally, MHPG concentrations were also lower in individuals with ADHD treated with SSRIs (general linear model, \( F = 4.3, p = 0.041 \)) or SNRI:s (general linear model, \( F = 4.8, p = 0.032 \)).

**Excluding patients with SSRIs**

Given the above association between SSRIs and 5-HIAA concentrations, the effect of diagnosis on 5-HIAA and MHPG concentrations was reassessed after exclusion of all patients treated with SSRIs. This analysis showed that individuals with bipolar disorder had higher 5-HIAA (mean concentration of 124 nmol/L after exclusion), significant Bonferroni post hoc test following ANOVA (\( F = 11.2, p < 0.001 \)) and lower MHPG (significant Bonferroni post...
hoc test following ANOVA, $F = 6.4$, $p = 0.002$) concentrations compared with both healthy controls and individuals with ADHD (mean 5-HIAA concentration of 107 nmol/L after exclusion).

**Discussion**

Our first finding is that patients with mood-stable bipolar disorder had higher HVA and 5-HIAA, but lower MHPG, concentrations than healthy controls. Second, patients with ADHD had higher HVA concentrations than controls. Third, the monoamine metabolite profile in bipolar disorder differed from ADHD: Whereas both patient groups demonstrated higher HVA than controls, MHPG was significantly lower in bipolar disorder compared with ADHD.

The strengths of the present study include a relatively large sample size and well-defined and distinct patient groups. We were also able to control for a number of confounding factors that hampered the previous studies. Specifically, we addressed whether altered CSF concentrations of monoamine metabolites are trait markers of bipolar disorder or rather related to mood state or medication effects. Furthermore, we included randomly sampled population-based control groups that were collected as a part of the same study and followed the same protocol as the patient groups. However, there are also some limitations to consider. The patient cohorts were collected in a naturalistic setting where they for ethical reasons continued to take their prescribed medications. Although we accounted for medication effects in the analyses, it cannot be excluded that there are cocktail or chronic effects of psychotropic medication that we cannot dissec out. Finally, the findings of our study are limited by the fact that we have only measured metabolites and not substrates nor additional metabolites such as 3,4-dihydroxyphenylacetic acid. However, a recent study has confirmed a correlative pattern between monoamine substrates and metabolites in brain tissue (Dellu-Hagedorn et al. 2017). In the ADHD group, childhood ADHD symptoms were assessed retrospectively using the anamnestic interview and WURS scales. Thus, it is possible that this group also includes cases of adult onset ADHD. Furthermore, intelligence quotient scores were not available for the study population.

**Bipolar disorder**

Patients with bipolar disorder featured higher CSF concentration of HVA and 5-HIAA, but lower concentration of MHPG. A previous study investigating CSF monoamine metabolite concentrations in mood-stable bipolar disorder patients found no difference as compared with a healthy control group (Berrettini et al. 1985). Given the relatively low number of study subjects in that study ($N = 55$) compared to ours (103 bipolar disorder subjects and 113 controls), it may, however, have been underpowered. However, the validity of our findings would be strengthened by an independent replication study.

In a previous study that included a subset of the patients in the Stockholm cohort, we found higher HVA concentrations only in mood-stable patients with a history of psychosis as compared to controls (Sellgren et al. 2015). We thus confirm this observation using a larger data set. In the study by Sellgren and co-workers, the increased HVA concentration in patients with a history of psychosis was suggested to be secondary to a kynurenic acid driven activation of the dopamine system. The association between HVA and psychotic symptoms is also supported by pharmacological evidence. Whereas dopamine agonists can trigger psychosis, a number of dopamine antagonists are effective against psychotic symptoms.

We found a low CSF concentration of MHPG in mood-stable bipolar patients, which is in line with a recent study that found low MHPG concentration in blood during remission in individuals with bipolar disorder (Kurita et al. 2014). Interestingly, other studies of acute mania (Swann et al. 1994) or atypical depression (Redmond et al. 1986) have demonstrated high MHPG concentrations in CSF in bipolar patients. Peripheral and central NE and MHPG concentrations have been found to be highly correlated (Kopin 1985), suggesting that sympathetic activity is an important determinant of CSF MHPG concentrations, which might, hence, be a state marker of mood episodes in bipolar disorder.

**Table 1 Characteristics of the study population**

|                      | Control group ($N = 113$) | Bipolar disorder group ($N = 103$) | ADHD group ($N = 72$) | Statistic | $p$ value |
|----------------------|---------------------------|-----------------------------------|-----------------------|-----------|-----------|
| Age$^a$              | 38 (13)                   | 40 (13)                           | 35 (10)               | $F$       | 2.3       | 0.10     |
| Height (m)$^a$       | 1.75 (0.10)               | 1.73 (0.10)                       | 1.75 (0.90)           | $\chi^2$  | 0.8       | 0.46     |
| Sex (female/male)    | 61/52                     | 60/43                             | 34/38                 | $F$       | 2.2       | 0.33     |

$^a$ Data presented as means (standard deviation)
There is limited previous work on CSF monoamine metabolite concentrations in adult ADHD. One study reported no difference in CSF HVA, 5-HIAA, and MHPG between attention-impaired children and a pediatric reference group (Cohen et al. 1977). There is some evidence of a correlation between monoamine metabolite concentrations and measures of aggression and impulsivity/hyperactivity (Castellanos et al. 1994). Furthermore, the same authors have shown HVA concentration to correlate with response to stimulant treatment (Castellanos et al. 1996). Our findings suggest that remitted adult individuals with ADHD show a measurable difference in dopamine metabolism as compared to healthy controls. One previous study has found high HVA concentration in ADHD patients that were non-responders to stimulant treatment (Reimherr et al. 1984). We found no relationship between monoamine metabolite concentrations and pharmacological treatment. Our power analysis indicated that only large effects would be reliably detected in the medication subgroups. Thus, there may be small or medium effects of medication that our study is not powered to detect. Furthermore, since only one patient in the cohort had a history of psychotic symptoms, the high HVA concentrations cannot be attributed to psychotic symptoms as suggested for the patients with bipolar disorder.

Using a sub-group of the present sample, we have previously shown an association between low HVA and 5-HIAA concentrations and childhood ADHD in bipolar I disorder (Ryden et al. 2009). In this larger sample, where individuals with comorbid ADHD were excluded, both similarities and differences were shown between bipolar disorder and ADHD. Whereas HVA concentrations were increased in both patients groups, 5-HIAA concentrations were higher only in the bipolar disorder group. The interpretation of 5-HIAA concentration might be confounded by SSRI treatment, but the exclusion of patients treated with SSRIs confirmed the initial analysis. Furthermore, the observation of low MHPG concentration in the bipolar disorder group was not shown for ADHD. This indicates a differential involvement of monoaminergic systems in bipolar disorder and ADHD.

**Medication**

SSRI treatment was linked to lower concentration of 5-HIAA in all patient groups in our study and this observation is in line with the previous clinical (Asberg and Wagner 1986; Nikisch et al. 2004; Walinder et al. 1981) and animal studies (Honig et al. 2009).

CSF monoamine metabolite concentrations have been used as indicators for monoamine turnover rates in the brain (Oreland et al. 1981). However, changes in monoamine metabolite concentrations are not readily translated into specific functional changes in monoamine signaling. Indeed, the bulk of detectable HVA and MHPG may be attributed to vesicular leakage rather than to activity dependent release (Eisenhofer et al. 2004). A previous
study has also shown that cerebrospinal fluid concentrations of HVA and 5-HIAA are positively correlated to cerebral energy metabolism in patients with mood disorders (Agren and Niklasson 1988).

Conclusion

The monoamine theory links changes in monoamine function to depressive and manic symptoms in bipolar disorder, and to attention-deficit and hyperactivity in ADHD. It has been suggested that such changes can be monitored using CSF measures of monoamine metabolites as proxy markers. In the largest study to date comparing healthy controls and individuals with bipolar disorder and ADHD, we show differences in CSF monoamine metabolites concentrations during symptom remission. Thus, altered monoamine metabolite concentrations appear to be markers of a trait dysfunction in brain monoaminergic systems.

Acknowledgements We wish to thank the staff at the St. Göran bipolar affective disorder unit, including study nurses Lena Lundberg and Benita Gezelius, and study coordinator Haydeh Olofsson. Yngve Hallström is acknowledged for performing lumbar punctures. Mathias Kardell is acknowledged for statistical and database support. We also thank the patients and controls participating in this study. We finally wish to thank the BBMRI.se and KI Biobank at Karolinska Institutet for professional biobank service.

Compliance with ethical standards

Funding This research was supported by Grants from the Swedish Medical Research Council (K2010-61P-21568-01-4, K2013-61X-14002, 2013-2546, K2014-62X-14647-12-51), the Swedish Foundation for Strategic Research (KF10-0039), The Swedish Brain Foundation, The Torsten Söderberg Foundation at the Royal Swedish Academy of Sciences, and the Swedish Federal Government under the LUA/ALF Agreement (ALF 20130032, ALFGBG-142041, ALFGBG-441051).

Conflict of interest The authors have no conflicts of interest to declare.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Agren H (1980) Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: I. General patterns. Psychiatry Res 3(2):211–223

Agren H, Niklasson F (1988) Creatinine and creatine in CSF: indices of brain energy metabolism in depression. Short note. J Neural Transm 74(1):55–59

Akiskal HS, McKinney WT Jr (1973) Depressive disorders: toward a unified hypothesis. Science 182(4107):20–29

Asberg M, Wagner A (1986) Biochemical effects of antidepressant treatment–studies of monoamine metabolites in cerebrospinal fluid and platelet \(^{3}H\)imipramine binding. Ciba Found Sympos 123:57–83

Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thoren P, Traskman-Bendz L (1984) CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69(3):201–219

Backman J, Alling C, Alsen M, Regnell G, Traskman-Bendz L (2000) Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment. Eur Neuropsychopharmacol 10(5):341–349

Berrettini WH, Nurnberger JJr, Scheinin M, Alsen M, Regnell G, Traskman-Bendz L (2000) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46(9):1234–1242

Blennew K, Wallin A, Gottfries CG, Karlsson I, Mansson JE, Skoog I, Wikkelso E, Svennerholm L (1993) Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18–88 years of age. Eur Neuropsychopharmacol 3(1):55–61

Bonvivini C, Faraone SV, Scassellati C (2016) Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry 21(7):872–884. doi: 10.1038/mp.2016.74

Castellanos FX, Elia J, Kruesi MJ, Gulotta CS, Mefford IN, Potter WZ, Ritchie GF, Rapoport JL (1994) Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res 52(3):305–316

Castellanos FX, Elia J, Krues MJ, Marsh WL, Gulotta CS, Potter WZ, Ritchie GF, Hamburger SD, Rapoport JL (1996) Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 14(2):125–137. doi: 10.1016/0893-133X(95)00077-G

Chaudhury D, Liu H, Han MH (2015) Neuronal correlates of depression. Cell Mol Life Sci 72(24):4825–4848. doi: 10.1007/s00018-015-2044-6

Cohen DJ, Carapulo BK, Shaywitz BA, Bowers MB Jr (1977) Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. CSF homovanillic acid and 5-hydroxyindoleacetic acid. Arch Gen Psychiatry 34(5):545–550

Dellu-Hagedorn F, Fitoussi A, De Deurwaerdere P (2017) Correlative analysis of dopamineergic and serotonergic metabolism across the brain to study monoaminergic function and interaction. J Neuroscience Methods 280:54–63. doi: 10.1016/j.jenmeth.2017.01.020

Eisenhofer G, Kopin JI, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56(3):331–349. doi: 10.1124/pr.56.3.1

Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M (2010) Manic episodes are associated with grey matter volume reduction—a voxel-based morphometry brain analysis. Acta Psychiatr Scand 122(6):507–515. doi: 10.1111/j.1600-0447.2010.01586.x

Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keyser CS (1990) Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 48(1):57–66

Fyro B, Petterson U, Sedwall G (1975) The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients. Psychopharmacologia 44(1):99–103

Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, Hare TA, Shaywitz BA, Cohen DJ (1984) CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 141(12):1533–1540

Goodwin FK, Ghaemi SN (1998) Understanding manic-depressive illness. Arch Gen Psychiatry 55(1):23–25

Honig G, Jongsma ME, van der Hart MC, Tecott LH (2009) Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. PLoS One 4(8):e26797. doi: 10.1371/journal.pone.0006797

Kasa K, Otsaki S, Yamamoto M, Sato M, Kuroda H, Ogawa H (1982) Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 17(8):877–883

Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE (2005) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 35(2):245–256

Kopin JI (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37(4):333–364

Kornetsky C (1970) Psychoactive drugs in the immature organism. Psychopharmacologia 17(2):105–136

Kurita M, Nishino S, Numata Y, Okubo Y, Sato T (2014) The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder. E: a clinical naturalistic study. PLoS One 9(6):e100634. doi: 10.1371/journal.pone.0100634

MacMillan V, Leake J, Chung T, Bovell M (1987) The effect of valproic acid on the 5-hydroxyindoleacetic, homovanillic and lactic acid levels of cerebrospinal fluid. Brain Res 420(2):268–276

Moir AT, Ashcroft GW, Crawford TB, Eccleston D, Guldberg HC (1970) Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 93(2):357–368

Nielsen JA, Moore KE (1982) Measurement of metabolites of dopamine and 5-hydroxytryptamine in cerebroventricular perfusates of unanaesthetized, freely-moving rats: selective effects of drugs. Pharmacol Biochem Behav 16(1):131–137

Nikisch G, Baumann P, Czernik A, Eap CB, Jimenez-Vasquez P, Moir AT, Ashcroft GW, Potter WZ, Mefford IN, Rapoport JL, Keysor MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE (2005) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 35(2):245–256

Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA (2010) Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome
and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol 30(5):496–503. doi: 10.1097/JCP.0b013e3181f2288e
Oreland L, Wiberg A, Asberg M, Traskman L, Sjostrand L, Thoren P, Bertilsson L, Tybring G (1981) Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Res 4(1):21–29
Owens MJ (2004) Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 65(Suppl 4):5–10
Peabody CA, Faull KF, King RJ, Whiteford HA, Barchas JD, Berger PA (1987) CSF amine metabolites and depression. Psychiatry Res 21(1):1–7
Redmond DE Jr, Katz MM, Maas JW, Swann A, Casper R, Davis JM (1986) Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry 43(10):938–947
Reimherr FW, Wender PH, Ebert MH, Wood DR (1984) Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res 11(1):71–78
Rucklidge JJ, Tannock R (2002) Validity of the Brown ADD scales: an investigation in a predominantly inattentive ADHD adolescent sample with and without reading disabilities. J Atten Disord 5(3):155–164. doi:10.1177/1087054702005000303
Ryden E, Johansson C, Blennow K, Landen M (2009) Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm 116(12):1667–1674. doi:10.1007/s00702-009-0300-3
Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53(11):1028–1042
Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS (2001) The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25(4):468–475. doi:10.1016/S0893-133X(01)00250-0
Sellgren CM, Kegel ME, Bergen SE, Ekman CI, Olsson S, Larsson M, Vawter MP, Backlund L, Sullivan PF, Sklar P, Smoller JW, Magnusson PK, Hultman CM, Walther-Jallow L, Svensson CI, Lichtenstein P, Schalling M, Engberg G, Erhardt S, Landen M (2015) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry. doi:10.1038/mp.2015.186
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33 (quiz 34–37)
Shah IR, Yatham LN (2000) Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2(2):77–92
Swann AC, Secunda S, Davis JM, Robins E, Hanin I, Koslow SH, Maas JW (1983) CSF monoamine metabolites in mania. Am J Psychiatry 140(4):396–400
Swann AC, Koslow SH, Katz MM, Maas JW, Javaid J, Secunda SK, Robins E (1987) Lithium carbonate treatment of mania. Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiatry 44(4):345–354
Swann AC, Stokes PE, Secunda SK, Maas JW, Bowden CL, Berman N, Koslow SH (1994) Depressive mania versus agitated depression: biogenic amine and hypothalamic–pituitary–adrenocortical function. Biol Psychiatry 35(10):803–813
Tissot R (1975) The common pathophysiology of monoaminergic psychoses: a new hypothesis. Neuropsychobiology 1(4):243–260
Walinder J, Carlsson A, Persson R (1981) 5-HT reuptake inhibitors plus tryptophan in endogenous depression. Acta Psychiatr Scand Suppl 290:179–190
Ward MF, Wender PH, Reimherr FW (1993) The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 150(6):885–890. doi:10.1176/ajp.150.6.885